Compared with the control antibody treatment, SIRPα-Fc treatment led to significant macrophage phagocytosis of bladder cancer cells expressing CD47 (p < 0.01) (Figure 2A–D), confirming the in vitro anti-tumor activity of blocking CD47. Here, SIRPA is linked to urinary bladder cancer.